{
  "docId": "019de072-c9ff-713b-84f0-a86291a57ca3",
  "docSlug": "36aaeca628c43c1081cab946857c1896",
  "documentTitle": "Navidea Biopharmaceuticals | Investor Presentation Deck | 18 slides",
  "authorId": "navidea-biopharmaceuticals",
  "authorName": "Navidea Biopharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 18,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "why_now",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a 'problem-solution' framing to justify the focus on RA.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c9ff-713b-84f0-a86291a57ca3/8",
  "deckHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3",
  "deckJsonHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3.json",
  "deckAnchorHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "list",
      "text": "There are many patients living with RA in the US (>1.3M by most estimates)\nCurrent treatments might work for a time but then typically fail\nAlmost all patients (>90%) are put on an anti-TNFa biologic therapy at some point in their treatment path- this is our first focus\nAbout half or more of these patients will fail to receive a clinically meaningful response!\nCurrent methods of assessing efficacy are subjective and are performed up to 6 months after a patient has started a drug\nDuring this time the disease might be getting worse, there are possible serious side effects, and the costs are high (~$3,000 per month)\nWhen drug is found to not be working, a “spin-the-wheel” attempt with new drug is made- cycle repeats\nA reliable, early predictor of treatment efficacy is needed- tilmanocept imaging\nMacrophages are the key target of anti-TNFa tx (and play a role in RA types and RA therapies), and tilmanocept imaging can quantify levels of macrophage involvement",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7013f678-a665-44f4-a097-97851073e78d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Hypothesis is that tilmanocept imaging can quantify whether a drug is working or likely to work earlier than is currently possible- even before the patient has started an anti-TNFa in some cases",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8aeb7ba1-fb77-40f4-8a11-32c0dcef06ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Large Unmet Need to Find the Best RA Tx for the Individual Patient",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0664f4a9-bdb6-4b65-9478-7eee1f9623eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Why Focus on Rheumatoid Arthritis?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a962edb-420e-489e-981c-0cef0d13bf57",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "problem-statement",
      "slug": null,
      "matchId": "c0b4d97e-8c44-4596-aaab-afd23ed87db1",
      "evidence": "The slide explicitly defines the clinical problem (ineffective RA treatment, long assessment times) and proposes a solution (tilmanocept imaging).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "10c3a14a-1f11-4583-ad6d-7527fe62932f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The sections on why focus on rheumatoid arthritis and the goals of completed and ongoing RA studies highlight the problem and complication.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "75bbb5a0-2fc1-4a9b-9ee5-ca90c2c5f615",
      "evidence": "The section on why focus on rheumatoid arthritis implies the cost of inaction.",
      "position": 0,
      "objective": "Highlight the cost of not addressing rheumatoid arthritis effectively",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}